FOR IMMEDIATE RELEASE
MapLight’s promising platform continues to garner support from leading Parkinson’s research foundation
SAN FRANCISCO, CA, August 4, 2021 – MapLight Therapeutics announced a $5.5M million grant from The Michael J. Fox Foundation for Parkinson’s Research to develop therapeutic treatments for levodopa-induced dyskinesia (LID). A side effect of the dopamine replacement therapy used to treat Parkinson’s disease, LID involves abnormal involuntary movements that can be as debilitating as Parkinson’s disease itself.
“We are grateful for the continued support of The Michael J. Fox Foundation as we work to understand and advance treatments for Parkinson’s disease,” said Anatol Kreitzer, Ph.D., Chief Discovery Officer at MapLight. “This funding is an important step in the advancement of an exciting, first-in-class therapeutic for a disabling condition that impacts many patients.”
Dopamine treatment can provide relief from the motor symptoms of Parkinson’s disease, such as tremor, rigidity, and slow movement. However, chronic use of dopamine and advancing disease can cause an imbalance of the neural pathways that activate and inhibit movement, leading to LID. The current standard-of-care treatment for LID, amantadine, is often ineffective and can significantly impair patient cognition.
MJFF will fund MapLight’s discovery and development efforts with $5.5 million over the course of three years. The project focuses on the potential of a novel G protein-coupled receptor to limit circuit dysfunction, reducing dyskinesia without triggering other unwanted side effects.
About MapLight Therapeutics
MapLight Therapeutics is developing targeted, highly effective therapeutics to improve the lives of those with difficult-to-treat brain disorders. Today, there are few therapeutic options for people living with conditions such as Autism Spectrum Disorder, Parkinson’s Disease, and Schizophrenia, and those therapies are limited by modest efficacy and significant side effects. MapLight is committed to redefining this standard of care. The company’s unique discovery platform combines novel, proprietary technologies to uncover the individual circuits that misfire in brain disorders and treat those circuits with effective, safe therapeutics. MapLight was founded in 2019 by a team of renowned neuroscientists who led the discovery of such groundbreaking technologies as optogenetics and STARmap. Learn more at www.maplightrx.com.
Media Contact for MapLight Therapeutics
Lauren Davis, Alkali Marketing, 512-751-2946